Trump administration advances plan to let compounding pharmacies make peptides

The Trump administration is moving forward with a policy to permit compounding pharmacies to produce certain peptides, a shift that could expand access but raise safety and regulatory concerns. The scope of peptides covered and the timeline remain unclear, and the move may face pushback from FDA officials and established manufacturers. This matters because it could alter the pharmaceutical supply landscape and create new market entrants.